Meir Wilchek
From Wikipedia, the free encyclopedia
| Meir Wilchek | |
 Meir Wilchek
|
|
| Born | 1935 Warsaw, Poland |
|---|---|
| Citizenship |  Israeli |
| Fields | Biochemist |
| Institutions | Weizmann Institute of Science |
| Alma mater | Bar Ilan University and the Weizmann Institute of Science |
| Known for | Affinity chromatography |
| Notable awards | Wolf Prize, Israel Prize |
| Religious stance | Orthodox Judaism |
Meir Wilchek (Hebrew: מאיר אשר וילצ'ק, born in 1935) is an Israeli biochemist. He is a professor at the Weizmann Institute of Science. In 1987, he won the Wolf Prize in Medicine along with Pedro Cuatrecasas "for the invention and development of affinity chromatography and its applications to biomedical sciences." [1]
Contents |
[edit] Early life and education
Meir Wilchek was born in Warsaw, Poland, scion of a rabbinical family. During the holocaust, he escaped from the german occupied territories to the territories occupied by Russia, and was transferred to Siberia, while his father, who served as a community rabbi in warsaw was killed in Flossenbürg concentration camp. He survived, and immigrated to Israel in 1949 with his mother and sister. He graduated with B.Sc. in chemistry from Bar Ilan university and Ph. D. in biochemistry from the Weizmann Institute of Science. Wilchek has published over 400 scientific papers, and consulted various biotech companies. He was also in the party list of Mafdal and Meimad for the Knesset.
[edit] Scientific Contributions
Meir Wilchek is known for his research in the field of biorecognition or affinity phenomenon, and its various application, e.g. for affinity chromatography, affinity labeling, affinity therapy, and the avidin-biotin system. The Avidin-biotin complex is the highest affinity interaction in nature, and its utilization to biochemistry integrates all of the former approaches.
Other contributions include conversion of serines to cysteines [2], and involvement with energy transfer studies between aromatic amino acids chromophores[3], an approach known today as FRET. He also studied the fine structure of these chromophores using circular dichroism [4]. More recently, he participated in a research team who studied how garlic works at the molecular level, thanks to a unique biotechnological procedure for producing large quantities of pure allicin, garlic's main biologically active component [5]
[edit] Affinity chromatography
Affinity chromatography[6] is a method of separating biochemical mixtures, based on a highly specific biologic interaction such as that between antigen and antibody, enzyme and substrate, or receptor and ligand. The method was subsequently adopted for a variety of other techniques. Specific uses of affinity chromatography include antibody affinity, Immobilized metal ion affinity chromatography and purification of recombinant proteins - possibly the most common use of the method. To purify, proteins are tagged e.g. using His-tags or GST (glutathione-S-transferase) tags, which can be recognized by a metal ion ligand, such as imidazole.
In 1971, Wilchek and colleagues applied this method to show that protein kinase is composed of regulatory and catalytic subunits[7]. In 1972, Wilchek showed that the method can be used to remove toxic compounds from blood, as exemplified by the removal of heme peptides from blood using immobilized human serum albumin, thus laying the grounds for modern hemoperfusion[8]
[edit] Affinity labeling
Affinity label is a molecule that is similar in structure to a particular substrate for a specific enzyme. It is considered to be a class of irreversible inhibitors. These molecules covalently modify active site residues in order to elucidate the structure of the active site. Using this method, Wilchek collaborated with a team who proved that the binding site of antibodies lies in the Fv portion of the molecule and involves three hypervariable sites, today called the complementarity-determining regions (CDRs[9]).
[edit] Affinity therapy
Affinity therapy, or immunotoxins is a biorecognition-based approach to selectively deliver a cytotoxic drug or toxin to a specific target cell. The field of affinity therapy was pioneered by Wilchek, together with Michael Sela, Ester Hurwitz, and Ruth Arnon. In 1975, they applied drug-conjugated antibodies for the targeted delivery of cytotoxic compounds to cancer cells[10]. They also demonstrated the advantage of having a polymeric spacer between the antibody and the drug and showed the effectiveness of conjugating simple polymers such as dextran for drug delivery and targeting. This approach was later adopted by others and eventually led to efficient treatment of human breast cancer by recombinant humanized anti-HER2 antibody (Herceptin) in a mixture with paclitaxel and doxorubicin. In 2003, Wilchek collaborated in a team who introduced a system based on antibody-directed enzyme prodrug therapy (ADEPT), using antibody-conjugated alliinase to produce a cytotoxic agent, allicin, in situ (at the site) of the cancer[11]
[edit] The avidin-biotin system
The avidin–biotin system is a technique for studying the interaction between two biomolecules in an indirect manner, as follows: Biotin is chemically coupled to a binder molecule (e.g., a protein, DNA, hormone, etc.) without disturbing the interaction with its target molecule; avidin is then used to “sandwich” between the biotinylated binder and a reporter molecule or probe. This allows for a variety of tasks, including localization and identification of the binder or target molecule. Consequently, the avidin-biotin system can frequently replace radioactive probes. Together with Ed Bayer, Wilchek established the Avidin-biotin system as a powerful tool in biological sciences. Early in the 1970s, they exploited Avidin as a probe and developed new methods and reagents to biotinylate antibodies and other biomolecules. Today, the system is applied in research and diagnostics as well as medical devices and pharmaceuticals. Examples include western blot, ELISA, ELISPOT and pull-down assays[12]. More recently, Wilchek participated in structural studies of the avidin–biotin complex, to characterize the unique properties of this strong interaction. The studies have culminated in the determination of the 3D structure of the avidin–biotin complex by X-ray crystallography[13], which aids in the design of specific artificial recognition sites[14].
[edit] Honors and awards
- 1981-1982 Fogarty International Scholar
- 1981 Honorary Member of the American Society of Biological Chemistry
- 1984 Rothschild Prize in Chemistry
- 1987 Wolf Prize in Medicine
- 1987 Pierce Prize for Biorecognition Technology
- 1988 Elected Member of the Israel Academy of Sciences and Humanities
- 1989 Doctor of Science, honoris causa, University of Waterloo, Canada
- 1989 Barnett Lecturer, Northeastern University, Boston
- 1990 Israel Prize in life sciences
- 1990 Sarstedt Prize (Numbrecht, Germany)
- 1993 Foreign Associate Member, Institute of Medicine, National Academy of Science, USA
- 1995 Doctor of Science, honoris causa, Bar Ilan Iniversity, Israel
- 1996 International Distinguished Clinical Chemist Award, International Federation of Clinical Chemistry (IFCC)
- 2000 Doctor of Science, honoris causa, University Jyvaskyla, Finland
- 2000 Honorary Doctorate, Ben-Gurion University of the Negev
- 2002 Honorary Citizen, City of Rehovot, Israel
- 2004 Christian B. Anfinsen Award of The Protein Society
- 2004 Wilhelm-Exner Medal, OGV, President of Austria
- 2005 Emet Prize, presented by the Prime Minister of Israel
[edit] References
- ^ The Wolf Prize in Medicine
- ^ Zioudrou, C., Wilchek, M., and Patchornik, A. (1965). "Conversion of the L-serine residue to an L-cysteine residue in peptides.". Biochemistry 4: 1811–1822.
- ^ Edelhoch, H., Brand, L., Wilchek, M. (1967). "Fluorescence studies with tryptophyl peptides.". Biochemistry 6: 547–559.
- ^ Edelhoch, H., Lippoldt, R.E., Wilchek, M. (1968). "The circular dichroism of tyrosyl and tryptophanyl diketopiperazines.". J. Biol. Chem. 243: 4799–4805.
- ^ English : PRESS
- ^ Cuatrecasas P, Wilchek M, and Anfinsen CB (1968). "Selective enzyme purification by affinity chromatography". Proc. Nat. Acad. Sci. USA 61: 636-43.
- ^ Wilchek, M., Salomon, Y., Lowe, M., and Selinger, Z. (1971). "Conversion of protein kinase to a cyclic AMP independent form by affinity chromatography on N0-caproyl 3′,5′-cyclic adenosine monophosphate-Sepharose.". Biochem. Biophys. Res. Commun. 45: 1177–1184.
- ^ Wilchek, M. (1972). "Purification of the heme peptide of cytochrome c by affinity chromatography.". Anal. Biochem. 49: 572–575.
- ^ Strausbauch, P.H., Weinstein, Y., Wilchek, M., Shaltiel, S.,Givol, D. (1971). "A homologous series of affinity labeling reagents and their use in the study of antibody binding sites". Biochemistry 10: 2631–2638.
- ^ Hurwitz, E., Levy, R., Maron, R., Wilchek, M., Arnon, R., and Sela, M. (1975). "The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities". Cancer Res. 35: 1175–1181.
- ^ Miron, T., Mironchik, M., Mirelman, D., Wilchek, M., and Rabinkov, A. (2003). "Inhibition of tumor growth by a novel approach: In situ allicin generation using targeted alliinase delivery.". Mol. Cancer Ther. 2: 1295–1301.
- ^ Wilchek, M., and Bayer, E.A. (1988). "The avidin-biotin complex in bioanalytical applications.". Anal. Biochem. 171: 1–32.
- ^ Livnah, O., Bayer, E.A., Wilchek, M., and Sussman, J. (1993). "Three-dimensional structures of avidin and the avidin-biotin complex.". Proc. Nat. Acad. Sci. 90: 5076–5080.
- ^ Domovich-Eisenberg, Y., Pazy, Y., Nir, O., Raboy, B., Bayer, E.A., Wilchek, M., and Livnah, O. (2004). "Structural elements responsible for conversion of streptavidin to a pseudoenzyme.". Proc. Nat. Acad. Sci. 101: 5916–5921.
